Clinical trials: Optic Nerve Diseases
Parkinson's Disease
Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain.
- Trial name
- NCT02610634
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
CLN3-related Disorders, Non-CLN3 Related Low Vision
Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision
Background: CLN3 involves vision loss observed around the preschool years, with eventual progression to blindness within 1-3 years.
- Trial name
- NCT04974307
- Testing
- OrCam MyEye 2
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near…
- Trial name
- NCT02363283
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Non-arteritic Ischemic Optic Neuropathy
Citicoline in Non-Arteritic Ischemic Optic Neuropathy
The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the…
- Trial name
- NCT03758118
- Testing
- Citicoline
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Retinopathy of Prematurity, Retinal Detachment
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be…
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Trial name
- ROP (NCT00634972)
- Testing
- ACULAR, REFRESH TEARS
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of South Alabama
Acute Stroke, Visual Field Loss
Fluoxetine for Visual Recovery After Ischemic Stroke
The purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.
- Trial name
- FLUORESCE (NCT02737930)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Bogachan Sahin
One Eye Blindness, Blind Left Eye
Multiplexing Prism Fitting for Field Expansion of Monocular Vision
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye).
- Conditions
- One Eye Blindness, Blind Left Eye, Blind Right Eye
- Trial name
- NCT06027216
- Testing
- Multiplexing Prism
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Diabetic Macular Edema
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLEAM (NCT04611152)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Germany and 6 more
- Volunteers
- 460 people
- Sponsor
- Kodiak Sciences Inc
Eye-tracking
EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2
This is a prospective multi-center cohort feasibility and exploratory study.
- Trial name
- ETA-TV (NCT02877732)
- Testing
- EYE-SYNC eye-tracking, SCAT-3 subtests, DEM
- Where
- 4 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Stanford University
Concussion, Mild, Convergence Insufficiency
Spectacles Lens in Concussed Kids
We will be looking at 3 treatment arms in the form of different type of glasses to see if one is superior to helping kids have sustained a concussion and are symptomatic.
- Conditions
- Concussion, Mild, Convergence Insufficiency, Accommodation; Insufficiency
- Trial name
- SLICK (NCT03123822)
- Testing
- Glasses
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Insomnia, Blindness
Melatonin for Circadian Sleep Disorders in the Blind
This research project consists of a three part study with five embedded sub studies. The first study phase identifies "body rhythms" of sleepiness/wakefulness and of melatonin levels for each subject (including sub-study 1).
- Conditions
- Insomnia, Blindness, Daytime Sleepiness
- Trial name
- NCT00911053
- Testing
- Melatonin, Regular Sleep Schedule, Light
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Oregon Health and Science University
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Low Vision, Both Eyes
Virtual Reality-Base Intelligent Orientation and Mobility Specialists Trial
The human subject research is a randomized, controlled training trial that tests the effectiveness of three Virtual Reality-based Intelligent Orientation and Mobility Specialists (VR-IOMSs) in teaching orientation and mobility…
- Trial name
- VR-IOMS (NCT04639531)
- Testing
- Orientation and Mobility Training with VR-IOMSs, Orientation and Mobility Training with COMS, No Orientation and Mobility Training
- Where
- 2 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Alabama at Birmingham
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Leber's Hereditary Optic Neuropathy (LHON)
Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
The purpose of this survey is to collect visual acuity data from patients with LHON in order to establish the clinical course (natural history) and visual acuity outcomes in patients with a genetically confirmed diagnosis of…
- Trial name
- NCT02796274
- Where
- 21 sites in Belgium, France and 5 more
- Volunteers
- 219 people
- Sponsor
- Santhera Pharmaceuticals
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Toxicity, Pupillary Miosis
Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
This study will establish the relationship between magnitude of opioid exposure and a pupillary measure referred to as PUAL (pupillary unrest in ambient light), in subjects aged 40-60.
- Conditions
- Opioid Toxicity, Pupillary Miosis, Respiratory Depression
- Trial name
- NCT05391555
- Testing
- Remifentanil Hydrochloride, Pupillometry measurement
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Diabetic Peripheral Neuropathy
Corneal Nerves Function and Structure
Peripheral neuropathy affects about 50% of the diabetic population and there is no treatment other than good blood glucose control, which is ineffective in subjects with type 2 diabetes.
- Trial name
- NCT04222660
- Testing
- Blackmores Omega Daily (4 1g capsules per day)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Central Vision Loss From Macular Diseases
Low Vision Intervention Trial II (LOVIT II)
This study will determine if the interdisciplinary team low vision rehabilitation program is more effective than basic low vision care provided by an optometrist working alone in improving visual reading ability in veterans with…
- Trial name
- LOVIT II (NCT00958360)
- Testing
- Interdisciplinary Low Vision Service, Basic Low Vision Service
- Where
- 7 sites in United States
- Volunteers
- 323 people
- Sponsor
- VA Office of Research and Development
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC